Glenmark introduces higher strength (400 mg) of FabiFlu? to reduce pill burden of COVID-19 treatment
- Glenmark is the first company in India?to have received the regulator's approval for 400 mg dosage form
- Increased strength of FabiFlu??yet another milestone effort by Glenmark's in-house R&D
- Patients can now opt for a more relaxed dosage regimen when compared to 200 mg tablet and now need to take half the number of pills?due to the introduction of 400 mg?
- Glenmark remains the only company in?India?to successfully complete a randomized, controlled, open-labelled, multi-center Phase 3 clinical trial on Indian patients with mild to moderate COVID-19